Carcinoid Syndrome Clinical Trial
Official title:
A Phase II, Open-Label, Single-Arm Study of INCMGA00012 and Telotristat Ethyl in Patients With Advanced Neuroendocrine Tumors and Carcinoid Syndrome
This phase II trial studies the effect of retifanlimab and telotristat ethyl in treating patients with neuroendocrine tumors that have spread to other places in the body (advanced) and carcinoid syndrome. Retifanlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Telotristat ethyl is a drug used to reduce side effects of carcinoid syndrome. Giving retifanlimab and telotristat ethyl may help to control neuroendocrine tumors in patients who also have carcinoid syndrome.
PRIMARY OBJECTIVE: I. To evaluate the efficacy of retifanlimab (A12) + telotristat ethyl (TE). SECONDARY OBJECTIVE: I. To evaluate the efficacy of A12 + TE. SAFETY OBJECTIVES: I. To evaluate the safety of A12 + TE. II. To evaluate the safety of withholding concurrent somatostatin analogue in patients receiving A12 + TE. EXPLORATORY BIOMARKER OBJECTIVE: I. To identify biomarkers that are predictive of response to A12 + TE (i.e., predictive biomarkers), are associated with progression to a more severe disease state (i.e., prognostic biomarkers), are associated with resistance to A12 + TE, are associated with susceptibility to developing adverse events, can provide evidence of study treatment activity, or can increase the knowledge and understanding of disease biology. OUTLINE: Patients receive retifanlimab intravenously (IV) over 30-60 minutes on day 1 and telotristat ethyl orally (PO) 3 times daily (TID) on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04993261 -
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
|
Early Phase 1 | |
| Not yet recruiting |
NCT04039516 -
Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy
|
Phase 2 | |
| Completed |
NCT01234168 -
A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
|
||
| Terminated |
NCT04073017 -
Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency
|
N/A | |
| Recruiting |
NCT05756608 -
Fibrosis in Chronic and Delayed Myocardial Infarction
|
||
| Completed |
NCT00774930 -
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
|
Phase 3 | |
| Withdrawn |
NCT04713202 -
Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl
|
Phase 2 | |
| Completed |
NCT00853047 -
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
|
Phase 2 | |
| Completed |
NCT02063659 -
Telotristat Etiprate for Carcinoid Syndrome Therapy
|
Phase 3 | |
| Completed |
NCT03223428 -
Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
|
||
| Recruiting |
NCT03453489 -
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm
|
Phase 2 | |
| Active, not recruiting |
NCT05361668 -
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
|
Phase 2 | |
| Completed |
NCT01104415 -
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
|
Phase 2 | |
| Withdrawn |
NCT01172717 -
Study of Panitumumab in the Treatment of Carcinoid Syndrome
|
Phase 2 | |
| Terminated |
NCT00884715 -
Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
|
Phase 1/Phase 2 | |
| Completed |
NCT01677910 -
TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
|
Phase 3 | |
| Completed |
NCT01430871 -
Effects of Serotonin Excess on Bone in Carcinoid Syndrome
|
N/A | |
| Completed |
NCT02026063 -
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
|
Phase 3 | |
| Terminated |
NCT01018953 -
Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
|
Phase 2 | |
| Terminated |
NCT04140409 -
Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation
|
Phase 4 |